RxDoctor Payments Data

William Tallmadge

Acute Care · Tyler, TXNPI 1912080813

Payments from drug & device makers

$7,695in general payments, 2019–2025

Across 475 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$814
  • Boehringer Ingelheim$691
  • Sanofi$591
  • Takeda Pharmaceuticals U.S.A., Inc.$385
  • Vertex$311
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,51698%
  • Education$1792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,695 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$25,755
Medicare patients
191
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft34$897,437
Aralast NpAlpha-1-Proteinase Inhibitor13$167,568
Prolastin CAlpha-1-Proteinase Inhibitor23$157,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter147$117,169
ZenpepLipase/Protease/Amylase14$114,651
SirturoBedaquiline Fumarate18$68,488
Breo ElliptaFluticasone/Vilanterol133$65,616
NucalaMepolizumab15$55,332
Dupixent SyringeDupilumab14$52,180
Spiriva RespimatTiotropium Bromide60$37,535
Spiriva HandihalerTiotropium Bromide35$28,097
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$26,422
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$23,168
Advair HfaFluticasone Propion/Salmeterol39$21,582
SymbicortBudesonide/Formoterol Fumarate63$15,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$311$897,43734 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta$1,835$259,099342 claims
Grifols USA, LLCProlastin C$86$157,94823 claims
Aimmune Therapeutics, Inc.Zenpep$69$114,65114 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$691$60,703105 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$814$47,181111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.

Other acute care in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →